SCHEDULE: Vanguard Discloses 0% Stake in Charles River Labs
Schedule 13G Amendment
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Charles River Laboratories International Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 14 to Schedule 13G regarding its beneficial ownership of Common Stock in Charles River Laboratories International Inc.
- The filing indicates that The Vanguard Group now holds 0.00 shares, representing 0% of the class of securities.
- This change is due to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It is an administrative update regarding The Vanguard Group's internal reporting structure for beneficial ownership, not a reflection of Charles River Laboratories International Inc.'s performance or a change in Vanguard's overall investment in the company.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Charles River Laboratories International Inc.'s future performance or operations.
Management Comments
- Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors (like Vanguard) holding more than 5% of a company's stock. This amendment indicates a change in how Vanguard reports its holdings, shifting from an aggregated to a disaggregated basis, which is an internal reporting adjustment rather than a change in investment strategy or a divestment from Charles River Laboratories International Inc. by Vanguard's overall managed funds.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Structure Realignment | The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026, leading to certain subsidiaries or business divisions reporting beneficial ownership separately (disaggregated basis) from The Vanguard Group, Inc. This means The Vanguard Group, Inc. no longer directly reports beneficial ownership over these specific securities. | 01/12/2026 | This change primarily affects how Vanguard's holdings are reported to the SEC, not the underlying investment decisions or the governance of Charles River Laboratories International Inc. It reflects an internal organizational decision by Vanguard to disaggregate its reporting. |
Stakeholder Impact
- Shareholders of Charles River Laboratories International Inc. will see a change in how The Vanguard Group's beneficial ownership is reported, with the parent entity now showing 0% due to disaggregated reporting by its subsidiaries. This does not imply a divestment by Vanguard's managed funds as a whole.
- Investment professionals will need to consider the disaggregated filings from Vanguard's subsidiaries to understand the full scope of Vanguard's collective beneficial ownership in Charles River Laboratories International Inc.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 01/12/2026 | Date of internal realignment within The Vanguard Group, Inc. |
| 03/13/2026 | Date of event which requires the filing of this statement. |
| 03/26/2026 | Date the statement was signed by Ashley Grim, Head of Global Fund Administration for The Vanguard Group. |
Keywords
Schedule 13G, Vanguard Group, Charles River Laboratories, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.